Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial-Reference-Cited by-同舟云学术

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial

Published:2020-10-23 Issue:24 Volume:9 Page:9246-9255
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med.

Author:

Tsuda Moe¹,Ishiguro Hiroshi²^ORCID,Toriguchi Naoko³,Masuda Norikazu⁴^ORCID,Bando Hiroko⁵,Ohgami Masahiro⁶,Homma Masato⁷,Morita Satoshi⁸,Yamamoto Naohito⁹,Kuroi Katsumasa¹⁰,Yanagita Yasuhiro¹¹,Takano Toshimi¹²^ORCID,Shimizu Satoru¹³,Toi Masakazu¹

Affiliation:

1. Department of Breast Surgery Graduate School of Medicine Kyoto University Kyoto Japan

2. Breast Oncology Service Saitama Medical University International Medical Center Hidaka Japan

3. Oncology Products Medicine Development Unit JapanEli Lilly Japan K.K Kobe Japan

4. Department of Surgery, Breast Oncology NHO Osaka National Hospital Osaka Japan

5. Breast and Endocrine Surgery Faculty of Medicine University of Tsukuba Tsukuba Japan

6. Department of Pharmacy Ibaraki Prefectural Central Hospital Kasama Japan

7. Department of Pharmaceutical Sciences Division of Clinical Medicine Faculty of Medicine University of Tsukuba Tsukuba Japan

8. Department of Biomedical Statistics and Bioinformatics. Graduate School of Medicine Kyoto University Kyoto Japan

9. Division of Breast Surgery Chiba Cancer Center Chiba Japan

10. Department of Breast Surgery Tokyo Metropolitan Health and Hospitals Corporation Ebara Hospital Tokyo Japan

11. Department of Breast Oncology Gunma Prefectural Cancer Center Gunma Japan

12. Breast Medical Oncology Breast Oncology Center The Cancer Institute Hospital of JFCR Tokyo Japan

13. Breast and Endocrine Surgery Kanagawa Cancer Center Yokohama Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3528

Reference26 articles.

1. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

3. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

4. Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

5. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment;Cancer Treatment Reviews;2024-05

2. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug–Drug Interaction and Improving Clinical Practice;Clinical Pharmacokinetics;2023-01

3. Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma;Journal of Translational Medicine;2021-10-29